Division of Eli Lilly & Co.
Latest From Dermira Inc.
Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.
Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
J.P. Morgan Notebook Day 2: Bourla Feels Pfizer's Underappreciated, GSK Prepares For Myeloma First And More
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: GSK's first-in-class oncology opportunity, Pfizer's Bourla on underappreciated pipeline, AstraZeneca's Enhertu pricing, Amgen's genomics push, Lilly filters through deals and Medicxi's de Rubertis teases big pharma CEOs about M&A.
- Large Molecule
- Topical Delivery
- Specialty Pharmaceuticals
- Drug Delivery
- Therapeutic Areas
- Skintelligence Inc.
- North America
- Parent & Subsidiaries
- Eli Lilly & Co.
- Senior Management
Thomas G Wiggans, CEO
Andrew Guggenhime, CFO
Eugene A Bauer, MD, CMO
Chrisotpher Griffith, Chief Business & Strategy Officer
Luis Pena, PhD, Chief Dev. Officer
Lori Lyons-Williams, Chief Commercial Officer
- Contact Info
Phone: (650) 421-7200
275 Middlefield Rd.
Menlo Park, CA 94025
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.